Falls Induced by Optogenetic Inhibition of Basal Forebrain Cholinergic Projections after Dorsomedial Striatal Dopamine Depletion in a Dual Disruption Model of Falling Vulnerability in Parkinson Disease

Falls are a common and debilitating feature of Parkinson’s Disease (PD) patients. They often serve as a precursor to serious injury or death. While the loss of dopamine in the striatum—the brain's motor coordination hub—is the hallmark of the disease, clinicians note that some patients suffer from extreme instability. Many of these patients experience gait issues that dopamine replacement therapy fails to resolve. This suggests a second culprit: the cholinergic system (a network of neurons that uses acetylcholine to regulate attention and sensory integration).

Current research identifies that deficits in prefrontal acetylcholine (ACh) and basal forebrain (BF) activity are linked to this increased fall risk. However, the precise relationship between these two failing systems remains poorly understood. It is unclear whether the loss of acetylcholine is a secondary symptom or a primary driver. Specifically, scientists want to know if cholinergic loss "unmasks" the underlying motor deficits caused by dopamine depletion. This paper addresses that gap. It uses high-resolution optogenetics (a technique using light to control specific neurons) to simulate transient cholinergic failures in a model of dopamine depletion.

The limits of single-system models

Historically, neurodegenerative research has treated Parkinson’s symptoms as discrete modules. Researchers could study dopamine depletion in isolation. Alternatively, they could look at cholinergic deficits separately. But in clinical reality, these systems do not fail in vacuums. Patients with both cognitive decline and motor impairment fall at significantly higher rates than those with motor deficits alone.

Existing animal models have struggled to capture this nuance. Earlier studies used chemogenetics—a method using engineered proteins called DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) to silence neurons for hours—to mimic cholinergic loss. While useful, chemogenetics lacks temporal precision. It provides a "tonic" or constant dampening of activity. This prevents researchers from studying "phasic" signaling (rapid, millisecond-scale bursts of neurotransmitters). Phasic signals are required for real-time adjustments during complex movement. Without the ability to disrupt acetylcholine at the exact moment of a physical challenge, we cannot see how the brain compensates for motor loss using cognitive resources.

Unmasking deficits through optogenetic disruption

To overcome the limitations of slow-acting drugs, the authors employed a wireless LED optogenetic system to achieve sub-second control over the basal forebrain. The methodology follows a three-stage architecture:

1. Dopamine Depletion: The researchers used 6-OHDA, a neurotoxin, to create partial lesions in the dorsomedial striatum of rats. This simulates the primary motor deficit of Parkinson's.
2. Targeted Cholinergic Silencing: Using a viral vector in ChAT-Cre rats (a genetic line where only cholinergic neurons express a specific marker), they expressed light-sensitive chloride channels in the basal forebrain. When blue light is delivered via wireless LEDs, these channels open. This allows negative ions to flow into the cells. This process transiently inhibits their activity.
3. Complex Motor Challenge: The rats performed the Michigan Complex Movement Control Task (MCMCT). This involved two environments: a straight rotating rod (low complexity) and a zig-zagging rotating rod (high complexity). The zig-zag rod is crucial. It requires the animal to constantly integrate spatial cues and adjust its posture. This process depends heavily on cholinergic-mediated attention.

By combining these methods, the authors created a "dual disruption" model. This allows them to observe how a sudden drop in attention interacts with a permanent deficit in motor control.

Statistical interactions on the zig-zag beam

The results suggest that the two deficits interact in a way that increases fall risk. The paper reports a significant interaction between the disruption group and the stimulation type. This effect was particularly evident during the zig-zag traversal.

On the straight rotating rod with 1s inhibitory LED pulses, falls rose from a baseline of 4.58±0.36 to 6.47±0.48 [Figure 1A]. However, the "Dual ACh/DA Disruption" group showed a significant interaction during continuous inhibition on the zig-zag rod. In these high-complexity trials, rats with both dopamine and acetylcholine disruptions fell more frequently than those with only one system impaired [Figure 1D]. Under continuous LED inhibition on the zig-zag rod, the Dual ACh/DA Disruption group averaged 9.44±1.00 falls. In comparison, the ACh Disruption Only group averaged 5.70±0.63 falls. The DA Lesion Only group averaged 5.00±0.73 falls.

The authors also quantified the biological drivers of this failure. Histological analysis showed that the severity of the dopamine lesion correlated with fall frequency on the zig-zag rod ($r = 0.52$, $p = 0.04$) [Figure 3H]. This was measured by TH staining (a marker for dopamine-producing neurons). Furthermore, the degree of optogenetic success correlated with the number of falls [Figure 3F]. Success was measured by how many cholinergic neurons were captured by the virus. This confirms that the observed instability is tied to the manipulated neural circuits.

Complexity and biological variability

Several nuances limit the immediate translation of these findings to clinical practice. First, the "zig-zag" task resulted in the exclusion of several rats. These animals were completely unable or unwilling to attempt the traversal. This suggests the model may encounter a threshold of difficulty. At this level, it becomes hard to distinguish between a controlled fall and a total failure of task engagement.

Second, the authors acknowledge the possibility of minor off-target expression. Most of the light-sensitive proteins were found in cholinergic cells (roughly 80% co-localization) .

However, a fraction of the expression occurred in non-cholinergic neurons. While the authors argue this effect is minimal, it remains a factor. Even slight non-specific inhibition could theoretically contribute to instability. Finally, the study does not address "dual-task" conditions. Real-world scenarios often require patients to navigate while simultaneously performing other cognitive tasks.

The verdict: A potential mechanism for falls

These results support the idea that combined striatal dopamine and cortical acetylcholine loss contributes to fall vulnerability. By using optogenetics, the authors showed that even transient interruptions in cholinergic signaling can precipitate falls in dopamine-depleted subjects. This suggests the brain may rely on a "cholinergic reserve" to compensate for motor instability.

This finding offers a potential explanation for why dopamine-centric treatments, like L-DOPA, sometimes fail to improve balance. If falls are driven by an inability to recruit cognitive resources, then focusing solely on dopamine may not suffice. Based on these rat models, the authors suggest that pro-cholinergic treatments might serve as beneficial adjunct therapies in humans. For patients with both cognitive and motor deficits, managing attentional health may be a vital step in mitigating gait and balance impairments.

Figures from the paper